$1.85
+0.06 (+3.35%)
Open$1.77
Previous Close$1.79
Day High$1.86
Day Low$1.74
52W High$7.80
52W Low$1.01
Volume—
Avg Volume946.5K
Market Cap123.72M
P/E Ratio—
EPS$-2.42
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,006.5% upside
Current
$1.85
$1.85
Target
$38.97
$38.97
$29.17
$38.97 avg
$44.78
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.00M | 76.19M | 65.35M |
| Net Income | -1,399,615 | -1,371,226 | -1,459,846 |
| Profit Margin | -1.8% | -1.8% | -2.2% |
| EBITDA | -1,495,155 | -1,465,448 | -1,363,438 |
| Free Cash Flow | -1,111,108 | -1,336,142 | -1,081,347 |
| Rev Growth | +16.0% | +7.1% | -1.4% |
| Debt/Equity | 0.13 | 0.12 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |